Moneycontrol PRO
Open App
you are here: HomeNewsDr reddys
dr reddys
Jump to
  • Dr Reddy's launches generic Revlimid in US market Sep 08, 2022 09:14 AM IST

    Dr Reddy's launches generic Revlimid in US market

    Celgene, the makers of Revlimid agreed to provide Dr. Reddy's with a licence to sell volume-limited amounts of generic lenalidomide capsules in the US in settlement of all outstanding claims of its litigation.

  • Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US Aug 14, 2022 12:01 PM IST

    Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US

    As per the latest Enforcement Report by USFDA, Mumbai-based drug firm Glenmark is recalling over 6.5 lakh tubes of a generic skin treatment ointment due to manufacturing issues.

  • Dr Reddy’s: China, India to lead EM opportunity Jul 29, 2022 12:29 PM IST

    Dr Reddy’s: China, India to lead EM opportunity

    The biggest focus area for Dr Reddy’s is Emerging Markets (EMs). Including India, EMs make up for 43 percent of its sales. In FY23, the company is targeting 130 launches in EMs, of which 30 would be for India

  • Dr Reddy's launches generic version of Allegra in US Jul 22, 2022 04:01 PM IST

    Dr Reddy's launches generic version of Allegra in US

    The Hyderabad-based drug firm said it has introduced Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg extended release tablets in the US market.

  • Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct Jul 13, 2022 07:33 PM IST

    Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct

    Net Sales are expected to increase by 7.7 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs 5,324.7 crore, according to ICICI Direct.

  • JB Chemicals gets board approval to acquire Dr Reddy's 4 brands Jun 30, 2022 11:45 AM IST

    JB Chemicals gets board approval to acquire Dr Reddy's 4 brands

    The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing.

  • Dr Reddy's settles patent litigation with Indivior, Aquestive Therapeutics Jun 30, 2022 10:40 AM IST

    Dr Reddy's settles patent litigation with Indivior, Aquestive Therapeutics

    A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties

  • From non-availability of boosters to pending visa clearances, no end to miseries for Sputnik V takers in India Jun 27, 2022 05:44 PM IST

    From non-availability of boosters to pending visa clearances, no end to miseries for Sputnik V takers in India

    While some people complained of the non-availability of Sputnik V booster doses in hospitals, when Moneycontrol reached out to Dr Reddy’s Laboratories Ltd, the manufacturers of Sputnik V vaccines in India, a company spokesperson said the booster dose is now available in partner hospitals in Hyderabad, New Delhi, Mumbai, and Pune, and is being extended to other hospitals and cities.

  • LIC increases stake in Dr Reddy’s from 3.64% to 5.65% Jun 16, 2022 07:07 PM IST

    LIC increases stake in Dr Reddy’s from 3.64% to 5.65%

    LIC said the holding increased from 3.644% to 5.646%, an increase of 2.002% during the period from September 3, 2021 to June 15, 2022 at an average cost of Rs 4670.46 per share.

  • Torrent Pharma acquires four brands from Dr Reddy’s Lab May 27, 2022 10:31 AM IST

    Torrent Pharma acquires four brands from Dr Reddy’s Lab

    According to the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India.

  • MCAtDavos Day 3 top newsmakers: Hardeep Singh Puri, Ronnie Screwvala, Kalyan Kumar and more May 25, 2022 07:15 PM IST

    MCAtDavos Day 3 top newsmakers: Hardeep Singh Puri, Ronnie Screwvala, Kalyan Kumar and more

    MCAtDavos Day 3 top newsmakers: This edition of the World Economic Forum holds special relevance, for it is after two years that the gathering has convened at Davos, in person. Coming to you at a time global politics is extremely polarised and a business order that is under duress, we will be telling you what are the issues the global leadership is talking about. Every evening, block your calendar, as we come to you with the day's top news from Davos, and the newsmakers.

  • #MCAtDavos Day 2 Top Newsmakers: Piyush Goyal, Tata Power, Infosys, Meesho, Zerodha & More May 24, 2022 07:36 PM IST

    #MCAtDavos Day 2 Top Newsmakers: Piyush Goyal, Tata Power, Infosys, Meesho, Zerodha & More

    #MCAtDavos Day-2: Special broadcast on Moneycontrol with all the day's big stories and headlines. This edition of the world economic forum holds special relevance, for it is after two years that the gathering has convened at Davos, in person. Coming to you at a time of extremely polarised global politics and a business order that is under duress, we will be telling you what are issues the global leadership is talking about. Every evening, block your calendar, as we come to you with the day's top news from Davos, and the newsmakers.

  • Live from World Economic Forum at Davos | India at 75: Strategic outlook May 24, 2022 04:20 PM IST

    Live from World Economic Forum at Davos | India at 75: Strategic outlook

    With its contributions to global economic growth and by ensuring that the world meets its climate and sustainability goals, India continues to emerge as an important global player. What actions can the country take to leverage today's inflection point and launch the reforms needed to be an influential member of the global community? CNBC-TV18's Shereen Bhan in conversation with Piyush Goyal, Minister of Commerce & Industry, Hardeep Singh Puri. Minister of Petroleum & Natural Gas, and Sanjiv Bajaj, Chairman & MD, Bajaj Finserv Ltd at the World Economic Forum in Davos.

  • Ukraine business is disrupted, Russian market remains unaffected: GV Prasad of Dr Reddy's May 24, 2022 03:44 PM IST

    Ukraine business is disrupted, Russian market remains unaffected: GV Prasad of Dr Reddy's

    GV Prasad, co-chairman and MD at Dr. Reddy's, shares his views on saturating vaccine demand, the impact of geopolitical tensions

  • Ideas For Profit | Dr Reddy’s: India, China & Russia opportunity to offset US pricing worries? May 20, 2022 05:47 PM IST

    Ideas For Profit | Dr Reddy’s: India, China & Russia opportunity to offset US pricing worries?

    Dr Reddy's stock is trading at 9.7x FY24e EV/EBITDA, which is at a discount to the median multiple for the sector. MC Pro believes steady traction in limited competition products and strong presence in emerging markets make the stock an accumulation candidate on declines. Watch the video to know about the key triggers and tailwinds for the company.

  • Dr Reddy’s: Acceleration in EM opportunity to help re-rate company May 20, 2022 10:59 AM IST

    Dr Reddy’s: Acceleration in EM opportunity to help re-rate company

    Dr Reddy’s area of focus in the domestic market includes hepatology, diabetic nutrition and its health-tech platform

  • Dr Reddy’s to reduce prices of Sputnik booster doses May 19, 2022 05:07 PM IST

    Dr Reddy’s to reduce prices of Sputnik booster doses

    Dr. Reddy has the rights to the marketing and distribution of the Russian COVID-19 vaccine in India.

  • Dr Reddy’s Q4 profit slides 76% due to impairment charges, firm to focus on growing core businesses May 19, 2022 03:44 PM IST

    Dr Reddy’s Q4 profit slides 76% due to impairment charges, firm to focus on growing core businesses

    The revenue for the quarter under review saw a growth of 15% at Rs 5,436.8 crore, up from Rs 4,728.4 crore a year ago

  • Pharma Q4 Preview | Despite strong domestic demand and modest US growth, cost pressure, lower prices to dent margins Apr 18, 2022 03:11 PM IST

    Pharma Q4 Preview | Despite strong domestic demand and modest US growth, cost pressure, lower prices to dent margins

    Raw material prices aggravated due to COVID-led lockdowns in China and spike in logistics costs to overshadow revenue growth

  • Dr Reddy’s to buy Novartis’s cardio drug Cidmus for Rs 463 crore Apr 01, 2022 08:56 PM IST

    Dr Reddy’s to buy Novartis’s cardio drug Cidmus for Rs 463 crore

    In a statement on April 1, Dr Reddy’s said the Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction.

  • Biocon, Dr Reddy's among 6 pharma majors in race to acquire Curatio Healthcare Mar 07, 2022 04:49 PM IST

    Biocon, Dr Reddy's among 6 pharma majors in race to acquire Curatio Healthcare

    Venture capital fund Sequoia holds a 33 percent stake in the company, Chryscapital 20 percent and the promoters, including GK Ramani, and the management hold the rest in Curatio

  • In Depth | As demand for COVID-19 vaccine dips in India, government and companies look to step up exports Mar 04, 2022 06:16 PM IST

    In Depth | As demand for COVID-19 vaccine dips in India, government and companies look to step up exports

    Average daily COVID-19 vaccinations in February dipped to 2-2.2 million from a high of nearly 8 million in August. The fall, coupled with a decline in the number of coronavirus disease cases, is prompting the Centre to give a push to vaccine exports.

  • DCGI gives nod to Sputnik Light vaccine in India, may be used as booster shot Feb 06, 2022 09:52 PM IST

    DCGI gives nod to Sputnik Light vaccine in India, may be used as booster shot

    The Russian COVID-19 vaccine Sputnik V has failed to take off in India despite being one of the first few vaccines approved and arrive but Sputnik Light, which is a single-dose vaccine, is expected to fare better, especially as it may be used as a booster shot.

  • Dr Reddy’s to enter medical cannabis business, to buy German firm Nimbus Feb 03, 2022 07:29 PM IST

    Dr Reddy’s to enter medical cannabis business, to buy German firm Nimbus

    The acquisition will allow it build on Nimbus Health’s strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, Dr Reddy’s said.

  • Dr Reddy’s: Supported by traction in limited competition products Jan 31, 2022 11:23 AM IST

    Dr Reddy’s: Supported by traction in limited competition products

    Sales growth in North America was helped by healthy market share for the generic version of Vascepa

Sections
ISO 27001 - BSI Assurance Mark